HIV-1 gp120 and gp41 Chimeric Antigen (43 kDa, Detection)

Name: HIV-1 gp120 and gp41 Chimeric Antigen (43 kDa, Detection)
SKU: DAGF-223
Rating: 5 (1 reviews)

HIV-1 gp120 and gp41 Chimeric Antigen (43 kDa, Detection), recombinant protein from E. coli

COA

SDS

Datasheet

Summary

Nature

Recombinant

Tag/Conjugate

proprietary

Molecular Weight

43 kDa

Alternative Names

Retroviridae;Lentivirus HIV;Human Immunodeficiency Virus type 1

Application Notes

Suitable for use in Lateral Flow. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Recommended pairs:
Capture Detection
DAGF-220 DAGF-223
DAGF-222 DAGF-223
DAGF-224 DAGF-223

Purity

≥ 90% Pure (Affinity Purified)

Format

Liquid

Concentration

Batch dependent - please inquire should you have specific requirements.

Buffer

20 mM Phosphate Buffer, 0.1% Sodium Dodecyl Sulfate, pH 7.4.

Preservative

None

Storage

May store at 2-8°C for < 2weeks. For long term, store at -20°C. Aliquot and freeze to avoid multiple freeze/thaw cycles.

Antigen Description

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.

Keywords

Retroviridae;Lentivirus HIV;Human Immunodeficiency Virus type 1

Citations

Have you cited DAGF-223 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Recruitment of US Adolescents and Young Adults (AYA) into Human Immunodeficiency Virus (HIV)-Related Behavioral Research Studies: A Scoping Review

CURRENT HIV/AIDS REPORTS

Authors: Navarra, Ann-Margaret Dunn; Handschuh, Caroline; Hroncich, Theresa; Jacobs, Susan Kaplan; Goldsamt, Lloyd

Abstract

Purpose of Review The objective of this scoping review was to examine the range of published evidence on recruitment approaches and outcomes of US adolescents and young adults (AYA) ages (18-29 years) into human immunodeficiency virus (HIV)-related behavioral research studies during the past 10 years. Recent Findings Implementation of effective behavioral research strategies among HIV at-risk and infected AYA is key to ending the HIV epidemic and necessitates successful recruitment strategies. A comprehensive search was executed across four electronic databases. Of the 1697 identified studies, seven met inclusion criteria with six of these seven directed to HIV prevention. Most studies used online recruitment as part of a hybrid strategy, and combined field-based/in-person and online methods. Recruitment strategies and outcomes, resources and compensation, procedures for consent, and timelines varied among all seven studies. Our results highlight the need for development of recruitment models in alignment with behavioral strategies aimed to treat and prevent HIV among US AYA.

Brain-derived neurotrophic factor (BDNF) is associated with depressive symptoms in older adults with HIV disease

JOURNAL OF NEUROVIROLOGY

Authors: Woods, Steven Paul; Babicz, Michelle; Shahani, Lokesh; Colpo, Gabriela Delevati; Morgan, Erin E.; Teixeira, Antonio L.

Abstract

Symptoms of depression are common among persons with HIV (PWH) and can have a significant impact on socioeconomic and personal well-being, but little is known about their neurobiological substrates in the context of HIV disease. This study examined the possible role of brain-derived neurotrophic factor (BDNF) in symptoms of depression and other aspects of mood in 109 PWH and 43 seronegative participants aged 50 and older. Participants completed the Profile of Mood States (POMS) which measured six dimensions of mood and was normatively adjusted for sex. A model controlling for medical comorbidities and substance use diagnoses among PWH showed a significant interaction between BDNF and POMS subscales. Planned post hoc analyses revealed that lower BDNF was only associated with higher scores on Depression-Dejection and Confusion-Bewilderment POMS subscales among PWH and at small-to-medium effect sizes. Lower levels of BDNF were associated with AIDS diagnoses and CD4 count, but not with viremia or duration of infection. BDNF levels did not differ between the PWH and HIV - samples, and there were no significant correlations between BDNF and any POMS variable in the HIV - group. Findings implicate BDNF in the neuropathophysiology of specific depressive symptoms in the context of HIV disease. Future studies may examine whether BDNF levels change over time, are sensitive to other aspects of mood disorders in HIV, and are associated with markers of HIV-associated neural injury.